MapLight Therapeutics, Inc. - 10-Q Filing
MapLight Therapeutics reports Q3 2025 financial results including research and development, general and administrative expenses, and updates on equity incentive plans.
Tickers: $MPLT
MapLight Therapeutics reports Q3 2025 financial results including research and development, general and administrative expenses, and updates on equity incentive plans.
Tickers: $MPLT